Benzinga · Mar 10, 2026
AP
NASDAQ · APM
Aptorum Group Limited
Healthcare · Biotechnology
$7.00
Down-$1.44 (-14.84%)
Updated Aug 14, 2026, 10:27 AM
SID Score
6.4/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 4.95M
- P/E ratio
- -2.69
- Dividend yield
- 0.00%
- 52-week range
- $0.65 – $8.33
- Volume
- 19.51K
- Avg. volume
- 51.44K
Price performance
APM price history
1M range · 0 trading sessions · Daily adjusted prices
APM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest APM news
The latest Smart Investors Daily articles mentioning APM.
Stock researchCompany · Overview
APM research
Overview
Company profile and research snapshot.
Company profile
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $81.60
- Implied upside
- —
- Analysts
- 6
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2022 | HC Wainwright & Co. | Buy | — |
| Apr 2, 2019 | China Renaissance | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 6, 2026
Aptorum Group Receives Nasdaq Noncompliance Notice
Yahoo · Feb 2, 2026
Aptorum Group Announces a Collaboration Between DiamiR Biosciences and Instant NanoBiosensors (INB) to Validate INB’s Automated APOE Testing Platform for Alzheimer’s Disease
NEW YORK, NY; NEW HAVEN, CT; PRINCETON, NJ, and TAIPEI, TAIWAN, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Instant NanoBiosensors Co., Ltd. (“INB”), a developer of cutting-edge biosensor platforms designed to improve bio
Benzinga · Feb 2, 2026
Aptorum Group, DiamiR Biosciences, Instant NanoBiosensors Collaborate To Validate Instant's Automated APOE Testing Platform
Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group" or "Aptorum"), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
